Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0224 | 0.5 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.0224 | 0.5 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0224 | 0.5 | 0.5 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0224 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0224 | 0.5 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.0224 | 0.5 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0224 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0224 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0224 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0224 | 0.5 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0224 | 0.5 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0224 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
k obs / 1 (binding) | = 250 M-1 s-1 | Apparent second order rate constant for inhibition of cathepsin B by fluorogenic assay. | ChEMBL. | No reference |
k obs / 1 (binding) | = 250 M-1 s-1 | Apparent second order rate constant for inhibition of cathepsin B by fluorogenic assay. | ChEMBL. | No reference |
k obs / 1 (binding) | = 2700 M-1 s-1 | Inhibition of cathepsin L (fluorogenic assay), apparent second order rate constant | ChEMBL. | No reference |
k obs / 1 (binding) | = 2700 M-1 s-1 | Inhibition of cathepsin L (fluorogenic assay), apparent second order rate constant | ChEMBL. | No reference |
k obs / 1 (binding) | = 11000 M-1 s-1 | Apparent second order rate constant for inhibition of calpain-1 by fluorogenic assay. | ChEMBL. | No reference |
k obs / 1 (binding) | = 11000 M-1 s-1 | Apparent second order rate constant for inhibition of calpain-1 by fluorogenic assay. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.